SIRT7 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL20153605	0.53	3/20
SCHEMBL29501829	0.48	3/20
SCHEMBL29501800	0.46	3/20
SCHEMBL12353901	0.45	3/20
SCHEMBL29569103	0.40	3/20
SCHEMBL29569256	0.40	3/20
Caprolactam (SCHEMBL3636353)	0.38	3/20
SCHEMBL23295889	0.31	2/20
SCHEMBL23328521	0.31	2/20
SCHEMBL14466945	0.71	1/20
SCHEMBL5317574	0.66	1/20
SCHEMBL180766	0.65	1/20
SCHEMBL5319106	0.64	1/20
SCHEMBL21303749	0.64	1/20
SCHEMBL5319550	0.61	1/20
SCHEMBL14466048	0.61	1/20
SCHEMBL5316742	0.60	1/20
SCHEMBL14465944	0.60	1/20
SCHEMBL5319878	0.59	1/20
SCHEMBL21311902	0.59	1/20

Clinical trials — most relevant to SIRT7 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Cardiotoxicity in Breast Cancer Patients	PHASE4	RECRUITING
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients	PHASE3	UNKNOWN
Sirtuin-NAD Activator in Alzheimer's Disease	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Nitrites, Skeletal Muscle Mitochondrial Bioenergetics, and Physical Activity in Old Age	PHASE2	COMPLETED
Oral Nitrite for Older Heart Failure Patients	PHASE2	COMPLETED
Effect of Pioglitazone Administered to Patients With Adrenomyeloneuropathy	PHASE2	COMPLETED
NADream: Effects of Nicotinamide Adenine Dinucleotide Supplementation on Sleep Quality in Healthy Individuals	PHASE2	RECRUITING
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults	PHASE2	RECRUITING
The Safety and Efficacy of an NAD+ Boosting Product Together With a Low Carbohydrate Diet in Adults With Mild Hypertension and Eligible for Normal-standard-of-care	PHASE2	COMPLETED
A Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT for the Treatment of Patients With HCC	PHASE2	COMPLETED
Nicotinamide Adenine Dinucleotide and Skeletal Muscle Metabolic Phenotype	PHASE2	UNKNOWN
Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults	PHASE1	RECRUITING
Tracing the Metabolic Flux of Orally Administered NAD+ Precursors	PHASE1	RECRUITING
Nicotinamide Riboside as an Enhancer of Exercise Therapy in Hypertensive Older Adults (The NEET Trial)	PHASE1	COMPLETED
Project SIRT6 Activator	nan	RECRUITING
How Sirtuin Levels Change During Behçet Disease	nan	UNKNOWN
Sirtuin 3 and Sirtuin 7 in Systemic Sclerosis	nan	UNKNOWN
Sirtuin1 in COVID19 Patients	nan	UNKNOWN
Influence of WNT4 VEZT FSHB and SIRT1 SNPs in Endometriosis: a Case Control Study of the Sardinian Population	nan	UNKNOWN
Impact of Nicotinamide Riboside (NR) on Kidney Function in Patients Undergoing Cardiac Surgery	nan	NOT_YET_RECRUITING
Comparison of Cardiometabolic Markers in Individuals With Hypertriglyceridemia With Low and High Weight Loss Responses to an Energy-restricted Diet	nan	COMPLETED
Inflammatory Axis and Sirtuins' in Overweight Pre-diabetics Patients	nan	COMPLETED
Short Interval Resveratrol Trial in Cardiovascular Surgery	nan	ACTIVE_NOT_RECRUITING
Effects of Protein Hydrolysate Supplement on Systemic Muscle Function Markers Following Resistance Type Exercise in Male Subjects	nan	COMPLETED
SWE to Detect Enthesitis in PsA: Relationship With SIRT2 Expression and Disease Activity	nan	NOT_YET_RECRUITING
Low Sirtuin-1 Levels Are Linked to Erythropoietin Resistance in Hemodialysis Patients.	nan	COMPLETED
Inflammation in COPD and the Effect of Nicotinamide Riboside	nan	COMPLETED
SIRT or TACE Plus Lenvatinib and PD-(L)1 Inhibitor in High Burden HCC	nan	COMPLETED
Expression of Longevity Genes in Response to Extended Fasting	nan	COMPLETED
Independent and Additive Effects Of Micronutrients With Metformin In Patients With PCOS	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SIRT7 binder may also engage these)

Protein	Name	Similarity
Q8BKJ9	—	1.000	Q8BKJ9 →
Q0P595	—	1.000	Q0P595 →
B2RZ55	—	1.000	B2RZ55 →
Q4R834	—	0.986	Q4R834 →
Q14147	—	0.982	Q14147 →
Q68FX9	—	0.980	Q68FX9 →
P40694	—	0.980	P40694 →
Q7XWV4	—	0.980	Q7XWV4 →
MACROD1	ADP-ribose glycohydrolase MACROD1	0.980	landscape →
Q5R6G3	—	0.979	Q5R6G3 →
Q9DBV3	—	0.978	Q9DBV3 →
Q9CXF7	—	0.978	Q9CXF7 →
Q8CG07	—	0.978	Q8CG07 →
Q9H6W3	—	0.978	Q9H6W3 →
SIRT2	NAD-dependent protein deacetylase sirtuin-2	0.978	landscape →
Q922B1	—	0.977	Q922B1 →
F7EZ75	—	0.977	F7EZ75 →
SIRT3	NAD-dependent protein deacetylase sirtuin-3, mitochondrial	0.977	landscape →
Q9Y4B4	—	0.977	Q9Y4B4 →
Q9NY93	—	0.977	Q9NY93 →
Q2KHU5	—	0.977	Q2KHU5 →
Q60560	—	0.977	Q60560 →
Q767K6	—	0.977	Q767K6 →
Q3ZBQ0	—	0.976	Q3ZBQ0 →
O60231	—	0.976	O60231 →
Q8VDQ8	—	0.976	Q8VDQ8 →
Q5RBF1	—	0.976	Q5RBF1 →
P23249	—	0.976	P23249 →
B8ARK7	—	0.976	B8ARK7 →
F7DKV7	—	0.976	F7DKV7 →